Vectors for gene therapy of cardiovascular disease

Current Cardiology Reports

Volumn 2, Issue 1, 2000, Pages 39-47

  Dedieu, Jean Francois ^a   Mahfoudi, Abderrahim ^a   Le Roux, Aude ^b   Branellec, Didier ^b  

^a Vector Development   (France)

^b Cardiovascular Department   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS; ADENOVIRUS; CARDIOVASCULAR DISEASE; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; LENTIVIRINAE; MURINE LEUKEMIA VIRUS; PLASMID; REVIEW;

ADENOVIRIDAE; CARDIOVASCULAR DISEASES; DEPENDOVIRUS; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; LEUKEMIA VIRUS, MURINE; PLASMIDS; TRANSDUCTION, GENETIC;

EID: 0033650681     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-000-0024-3     Document Type: Article

References (51)

1. Laitinen M, Pakkanen T, Donetti E, et al. : Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses and adenoviruses. Hum Gene Ther 1997, 8:1645 1650.
2. Losordo DW, Vale PR, Isner JM: Gene therapy for myocardial angiogenesis. Am Heart J 1999, 138:132-141.
3. Rosengart T, Lee L, Patel S, et al. : Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999, 100:468 474.
4. Phillips M: Is gene therapy for hypertension possible? Hypertension 1999, 33:8-13.
5. Laitinen M , Yla-Herttuala S: Vascular gene transfer for th treatment of restenosis and atherosclerosis. Curr Opin Lipidol 1998, 9:465-469.
6. Harvey BG, Hackett NR, El-Sawy T, et al. : Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol 1999, 73:6729-6742.
7. Mack C, Song W, Carpenter H, et al. : Circumvention of antiadenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997, 8:99-109.
8. Hofmann C, Löser P, Cichon G, et al. : Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. J Virol 1999, 73:6930-6936.
9. O'Riordan CR, Lachapelle A, Delgado C, et al. : PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999, 10:1349-1358.
10. Tripathy S, Black H, Goldwasser E, Leiden J: Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med 1996, 2:545-550.
11. Dedieu JF, Vigne E, Torrent C, et al. : Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 1997, 71: 4626 4637.
12. Gao GP, Yang YP, Wilson JM: Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996, 70:8934-8943.
13. Gorziglia M, Lapcevich C, Roy S, et al. : Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3. J Virol 1999, 73 6048-6055.
14. Wang Q, Greenburg G, Bunch D, Farson D, Finer M: Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. Gene Ther 1997, 4:393-400.
15. Morsy M, Gu M, Motzel S, et al. : An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A 1998, 95 7866-7871.
16. Chen H, Mack L, Choi S, Ontell M, et al. : DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. Hum Gene Ther 1999, 10:365-373.
17. Perlman H, Luo Z, Krasinski K, et al. : Adenovirus-mediated delivery of the Gax transcription factor to rat carotid arteries inhibits smooth muscle proliferation and induces apoptosis. Gene Ther 1999, 6:758-763.
18. Rekhter M, Simari R, Work C, et al. : Gene transfer into normal and atherosclerotic human blood vessels. Circ Res 1998, 82:1243 1252.
19. Vigne E, Mahfouz I, Dedieu JF, et al. : RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 1999, 73 5156-5161.
20. Wickham T, Tzen E, Shears LN, et al. : Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997, 71:8221-8229.
21. Patijn GA , Kay MA: Hepatic gene therapy using adeno-associated virus vectors. Semin Liver Dis 1999, 19:61-69.
22. Marshall DJ , Leiden JM: Recent advances in skeletal-musclebased gene therapy. Curr Opin Genet Dev 1998, 8:360-365.
23. Nakai H, Iwaki Y, Kay MA, Couto LB: Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol 1999, 73:5438-5447.
24. Jooss K, Yang Y, Fisher KJ, Wilson JM: Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998, 72:4212-4223
25. Murphy JE, Zhou S, Giese K, et al. : Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin. Proc Natl Acad Sci U S A 1997, 94:13921-13926.
26. Herzog RW, Yang EY, Couto LB, et al. : Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Genet 1999, 5:56-63.
27. Kaplitt MG, Xiao X, Samulski RJ, et al. : Long-term gene transfer in porcine myocardium after coronary infusion of an adenoassociated virus vector. Ann Thorac Sur 1996, 62:1669 1676.
28. Svensson EC, Marshall DJ, Woodard K, et al. : Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation 1999, 99:201-205.
29. Rolling F, Nong Z, Pisvin S, Collen D: Adeno-associated virusmediated gene transfer into rat carotid arteries. Gene Ther 1997, 4:757-761.
30. Lynch CM, Hara PS, Leonard JC, et al. : Adeno-associated virus vectors for vascular gene delivery. Circ Res 1997, 80:497-505.
31. Salvetti A, Oreve S, Chadeuf G, et al. : Factors influencing recombinant adeno-associated virus production. Hum Gene Ther 1998, 9:695 706.
32. Gao GP, Qu G, Faust LZ, et al. : High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther 1998, 9:2353-2362.
33. Inoue N , Russell DW: Packaging cells based on inducible gene amplification for the production of adeno-associated virus vector. J Virol 1998, 72:7024-7031.
34. Matsushita T, Elliger S, Elliger C, et al. : Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 1998, 5:938 945.
35. Xiao X, Li J, Samulski RJ: Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998 72:2224-2232.
36. Manning WC, Zhou S, Bland MP, et al. : Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum Gene Ther 1998, 19:477-485.
37. Xiao W, Chirmule N, Berta SC, et al. : Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999, 73:3994-4003.
38. Bohl D, Salvetti A, Moullier P, Heard J: Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood 1998, 92:1512-1517.
39. Ye X, Rivera VM, Zoltick P, et al. : Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 1999, 283:88-91.
40. Prentice H, Kloner RA, Li Y, et al. : Ischemic/reperfused myocardium can express recombinant protein following direct DNA or retroviral injection. J Mol Cell Cardiol 1996, 28:133-140.
41. Zhu NL, Wu L, Liu PX, et al. : Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation Circulation 1997, 96:628-635.
42. Flugelman MY: Inhibition of intravascular thrombosis and vascular smooth muscle cell proliferation by gene therapy. Thromb Haemost 1995, 74:406-410.
43. DePolo NJ, Harkleroad CE, Bodner M, et al. : The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. J Virol 1999, 73 6708-6714.
44. Hall FL, Gordon EM, Wu L, et al. : Targeting retroviral vectors to vascular lesions by genetic engineering of the MoML gp70 envelope protein. Hum Gene Ther 1997, 8:2183-2192.
45. Zhao Y, Zhu L, Lee S, et al. : Identification of the block in targeted retroviral-mediated gene transfer Proc Natl Acad Sci U S A 1999, 96 4005-4010.
46. Martin F, Neil S, Kupsch J, et al. : Retrovirus targeting by tropism restriction to melanoma cells. J Virol 1999, 73:6923 6929.
47. Powell C, Shansky J, Del Tatto M, et al. : Tissue-engineered human bioartificial muscles expressing a foreign recombinant protein for gene therapy. Hum Gene Ther 1999, 10:565-577
48. Kullo IJ, Simari RD, Schwartz RS: Vascular gene transfer. Arterioscler Thromb Vasc Biol 1999, 19:196-207.
49. Naldini L: Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol 1998, 9:457-463.
50. Kafri T, Blömer U, Peterson DA, et al. : Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997, 17 314-317.
51. Mochizuki H, Schwartz JP, Tanaka K, et al. : High-titer human immunodeficiency virus type 1-based vector system for gene delivery into nondividing cells. J Virol 1998, 72:8873-8883.